{
    "clinical_study": {
        "@rank": "97332", 
        "arm_group": {
            "arm_group_label": "MP-424(+RBV+PEG-IFN alfa-2a)", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy and safety of MP-424 with PEG-IFN Alfa-2a and RBV in\n      patients with genotype 1 hepatitis C, who are na\u00efve to its treatment or relapsed after\n      previous treatment."
        }, 
        "brief_title": "Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Na\u00efve or Relapsed Hepatitis C", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis C (CHC)", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Genotype 1  CHC\n\n          -  treatment-na\u00efve or relapsers (patient who relapsed after previous treatment)\n\n          -  Able and willing to follow contraception requirements\n\n        Exclusion Criteria:\n\n          -  Cirrhosis of the liver or hepatic failure\n\n          -  Hepatitis B surface antigen-positive or HIV (Human Immunodeficiency Virus)\n             antibodies-positive\n\n          -  History of, or concurrent hepatocellular carcinoma\n\n          -  History of, or concurrent depression, schizophrenia, or suicide attempt in the past\n\n          -  Pregnant, lactating, or suspected pregnant patients, or male patients whose female\n             partner is pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01753557", 
            "org_study_id": "G060-A12"
        }, 
        "intervention": [
            {
                "arm_group_label": "MP-424(+RBV+PEG-IFN alfa-2a)", 
                "description": "MP-424: 750mg every 8 hours (q8h) for 12 weeks", 
                "intervention_name": "MP-424", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MP-424(+RBV+PEG-IFN alfa-2a)", 
                "description": "RBV: 600 - 1000 mg/day based on body weight for 24 weeks", 
                "intervention_name": "RBV", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MP-424(+RBV+PEG-IFN alfa-2a)", 
                "description": "PEG-IFN alfa-2a: 180mcg/week for 24 weeks", 
                "intervention_name": "PEG-IFN alfa-2a", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon Alfa-2a", 
                "Interferon-alpha", 
                "Peginterferon alfa-2a"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pegasys", 
        "lastchanged_date": "January 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kawasaki City", 
                    "country": "Japan", 
                    "state": "Takatsu-ku", 
                    "zip": "213-8587"
                }, 
                "name": "Toranomon Hospital"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 3 Study of MP-424 in Combination With PEG-IFN Alfa-2a and RBV, in Subjects With Genotype 1 Hepatitis C, Who Are Treatment-Na\u00efve or Relapsed After Previous Treatment", 
        "overall_official": {
            "affiliation": "Mitsubishi Tanabe Pharma Corporation", 
            "last_name": "Kazuoki Kondo, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 weeks after completion of drug administration (SVR, sustained viral response)", 
            "safety_issue": "No", 
            "time_frame": "48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01753557"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Undetectable HCV RNA at 4 weeks after beginning  of drug administration (RVR, rapid viral response)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Undetectable HCV RNA at completion of drug administration (ETR, end-of-treatment response)", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Undetectable HCV RNA at 12 weeks after completion of drug administration", 
                "safety_issue": "No", 
                "time_frame": "36 weeks"
            }, 
            {
                "measure": "Transition of serum HCV RNA levels", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 24 weeks after completion of drug administration"
            }, 
            {
                "measure": "Viral sequencing at the NS3 protease region of HCV virus", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 24 weeks after completion of drug administration"
            }
        ], 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}